Record-Breaking Compensation Package for Novartis CEO Sparks Controversy

A staggering CHF 19.2 million. That is the price tag for leadership at Novartis in 2024, and it has triggered an immediate and fierce rebuke from Switzerland's leading pension fund consultancy. The Ethos Foundation has officially recommended that shareholders vote against all compensation-related items at the pharmaceutical giant's upcoming Annual General Meeting on March 7. This is not merely a disagreement over figures; it is a fundamental clash over corporate governance principles in the heart of Basel.

Ethos is drawing a hard line in the sand. The foundation contends that CEO Vasant Narasimhan’s compensation package—the highest recorded since 2009—represents an unacceptable escalation in executive greed. While Novartis delivered relatively strong financial performance in 2024, Ethos argues that the sheer magnitude of this payout disconnects executive rewards from reasonable societal standards. This recommendation serves as a critical wake-up call to the board: institutional investors are watching, and their patience for skyrocketing paychecks is rapidly evaporating.

Trust is eroding as fast as the salaries are rising. When Vasant Narasimhan took the helm in 2018, his remuneration stood at approximately CHF 10 million—a figure the company touted as proof that the era of exorbitant payouts was over. Fast forward to today, and that figure has nearly doubled. "The company assured us at the time that excesses were a thing of the past," stated Vincent Kaufmann, director of the Ethos Foundation, highlighting a glaring disconnect between past assurances and present realities.

This dramatic surge to CHF 19.2 million is driven by aggressive variable compensation targets and leverage effects that have amplified the CEO's earnings far beyond the initial baseline. Critics argue this trajectory signals a return to the 'fat cat' culture that Swiss corporate governance has struggled to curb for decades. The doubling of the CEO's pay in just six years raises uncomfortable questions about the effectiveness of current restraint mechanisms and whether the board has abandoned its commitment to moderation.

Novartis is once again grappling with the ghosts of its own history. The current controversy inevitably draws comparisons to the era of Daniel Vasella, whose astronomical CHF 42 million payout in 2009 sparked nationwide outrage and fueled the 'Minder Initiative' against excessive executive pay. While Narasimhan's CHF 19.2 million does not yet reach those dizzying heights, the trend line is unmistakably pointing upward, reigniting fears that the pharmaceutical titan is sliding back into old, unpopular habits.

For the Swiss public and shareholders alike, the specter of the Vasella era serves as a cautionary tale of corporate hubris. The current payout is the highest since that tumultuous period, signaling a dangerous drift away from the post-Vasella reforms. By allowing compensation to creep back toward these historic highs, the Novartis board risks reopening old wounds and inviting renewed scrutiny from a public that has long been skeptical of multinational corporate excesses.

The battle lines are drawn for March 7. Beyond the CEO's paycheck, Ethos is mobilizing to reject the board's proposal for a maximum remuneration pool of CHF 95 million for the eleven-member Executive Board in 2026. This preemptive strike targets the future financial architecture of the company's leadership, signaling that investors are unwilling to write blank checks for the years ahead. The message is clear: good financial performance does not justify limitless remuneration.

This upcoming vote is a critical test for shareholder activism in Switzerland. If Ethos succeeds in rallying a significant blockade, it will send a shockwave through the Swiss corporate landscape, warning other multinationals that the ceiling for executive pay is solidifying. Conversely, if the measures pass easily, it may embolden boards across the sector to push the envelope further. All eyes are now on Basel, where shareholders must decide whether to endorse the status quo or demand a return to the moderation they were once promised.